Epidemiology of Viral Induced Anterior Uveitis

Radosavljević, Aleksandra; Agarwal, Mamta; Zierhut, Manfred

doi:10.1080/09273948.2020.1853177

Cited by 15 publications

(8 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The type of infection that may reactivate may be influenced by geography with infections common in Asia such as toxoplasma and CMV being less common in the West. Given the epidemiological differences of viral-induced uveitis in Asia compared to the West (30), it is important to be aware of this. In our study, there was 50% infection and 50% NIAU.…”

Section: Discussionmentioning

confidence: 99%

Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center

Chew

Wiryasaputra

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundWe report vaccine and booster-related uveitis in Singapore, a country with high vaccination and booster rates to highlight the differences and potential role of prophylactic treatment for sight-threatening infectious uveitis.MethodsClinical data extracted from the de-identified uveitis database in Singapore National Eye Center. Six patients (eight eyes) developed uveitis within 14 days after undergoing COVID-19 vaccination (primary and/or booster).ResultsAll patients received two doses of COVID-19 vaccination, and 1.39% (6/431) developed COVID-19 vaccine-related uveitis. Fifty-percent% (3/6) with non-infectious anterior uveitis (NIAU) presented with a non-granulomatous anterior uveitis (AU). The remaining (3/6) presenting with a granulomatous AU were diagnosed with reactivation of cytomegalovirus, varicella-zoster virus and toxoplasma chorioretinitis, respectively. All the patients responded to definitive treatment specific to their diagnosis. The mean visual acuity at presentation was 0.36 ± 0.20 logMAR and improved to 0.75 ± 0.09 (p = 0.009). Mean time from vaccination to uveitis was 9.7 (range: 3–14) days. All patients developed uveitis after second vaccination dose. 16.67% (1/6) patients had a recurrence after the third booster dose. None of the three patients with infectious uveitis developed recurrence but had received maintenance therapy up to or during the booster.ConclusionUveitis after COVID-19 vaccination is uncommon. In our series, a higher rate of reactivations of latent infections was seen. With definitive treatment, all cases were self-limited without systemic sequelae. Prophylactic treatment during booster vaccine may prevent reactivation of sight-threatening infections and reduce morbidity although risk-benefits should be considered for individual patients given the low rate of occurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center

Chew

Wiryasaputra

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

Section: Epidemiologymentioning

confidence: 99%

“…According to a recent metaanalysis [1], HSV and VZV are the most prevalent causes of viral AU worldwide, whereas CMV is found mainly in Asian patients. Other causes of virus associated AU include endemic viruses such as (more commonly) rubella virus and others such as HTLV-1, chikungunya, dengue, Ebola, and Zika virus, although these play a much smaller role than the former and usually do not induce purely anterior inflammation [1]. The age distribution varies somewhat depending on the virus: HSV associated uveitis usually manifests between the 4th and 6th decade of life, whereas the VZV associated variety tends to present around the age of 60 to 70 [2].…”

Section: Epidemiologymentioning

confidence: 99%

“…Weltweit sind nach einer aktuellen Metaanalyse [1] das Herpessimplex-Virus (HSV) und das Varicella-zoster-Virus (VZV) die häufigsten Auslöser einer viralen AU, wohingegen das Zytomegalievirus (CMV) vor allem bei asiatischen Patienten gehäuft auftritt. Weitere Ursachen einer virusassoziierten AU können endemisch vorkommende Viren wie (häufiger) das Rubellavirus sowie andere, wie das Humane T-lymphotrope Virus 1 (HTLV-1), Chikungunya, Dengue, Ebola oder das Zikavirus, sein, wobei diese eine weitaus geringere Rolle spielen als die vorgenannten und i. d. R. auch keine rein anteriore Entzündung hervorrufen [1]. Die Altersverteilung ist je nach Virus etwas unterschiedlich: HSV-assoziierte Uveitiden manifestieren sich meist zwischen der 4. und 6.…”

Section: Epidemiologieunclassified

See 1 more Smart Citation

Virale anteriore Uveitis

Baquet-Walscheid

Pohlmann

Pleyer

2022

Klin Monbl Augenheilkd

View full text Add to dashboard Cite

ZusammenfassungVirale anteriore Uveitiden (AU) lassen sich anhand der charakteristischen Befundkonstellationen (Vorderkammerreiz, Morphologie der Keratopräzipitate, Ausmaß des IOD-Anstiegs im Schub) oft gut klinisch differenzieren. Bei differenzialdiagnostischen Schwierigkeiten hilft die Vorderkammerpunktion mit Durchführung einer virusspezifischen PCR und/oder die Antikörperbestimmung (Goldmann-Witmer-Koeffizient), wobei beide Techniken spezifisch sind, aber keine absolute Sensitivität besitzen. Therapiert wird bei HSV, VZV und CMV immer kombiniert antiviral und antiinflammatorisch sowie ggf. drucksenkend, wohingegen für die Rubella-assoziierte AU kein spezifisches Virustatikum existiert und Steroide aufgrund der unerwünschten Wirkungen äußerst zurückhaltend eingesetzt werden sollten. Problematisch bei allen Formen der viralen AU ist das Risiko der Sekundärglaukomentwicklung im Falle rezidivierender Episoden, das nicht selten operativ behandelt werden muss.

show abstract

“…Uveitis refers to various intraocular inflammatory diseases occurred in uvea (i.e., iris, ciliary body, and choroid) and its adjacent structures (including cornea, vitreous body, retina, and optic nerve) [ 1 ]. Without timely diagnosis and treatment on chronic inflammation in the eye, it will lead to cataracts, glaucoma, corneal lesion, macular edema, or even permanent vision loss [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Research Progress on the Mechanism of Natural Product Ingredients in the Treatment of Uveitis

Liu

Zhang

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

As the spectrum of ophthalmic diseases keeps changing, uveitis has gradually become one of the major blinding eye diseases in the world. Although the efficacy and safety of adalimumab and other biological agents in the treatment of uveitis have been proved in clinical studies, no biological agents have been approved for the treatment of uveitis by Chinese National Medical Products Administration (NMPA). The quality of life and prognosis of uveitis patients are affected by the adverse reactions of currently available immunosuppressive drugs. In recent years, it has become a research hotspot to select effective components for uveitis treatment from natural drugs. Based on the classification of chemical structure, the therapeutic effect and mechanism of natural drug components on uveitis were discussed in detail, in order to provide reference for basic drug development and clinical research.

show abstract

Epidemiology of Viral Induced Anterior Uveitis

Cited by 15 publications

References 129 publications

Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center

Incidence of COVID-19 Vaccination-Related Uveitis and Effects of Booster Dose in a Tertiary Uveitis Referral Center

Virale anteriore Uveitis

Research Progress on the Mechanism of Natural Product Ingredients in the Treatment of Uveitis

Contact Info

Product

Resources

About